Clinical trial · Observational
Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma
In Vivo Imaging of Effector Cells in Anti-Lymphoma Therapy
NCT00897923CI-TRIAL-00026569completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Measuring the number of radiolabeled white blood cells in non-Hodgkin's lymphoma tumors may help doctors predict how well patients will respond to treatment, and may help the study of cancer in the future. PURPOSE: This study is measuring radiolabeled white blood cells in patients with non-Hodgkin's lymphoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Small Intestine Cancer | Small Intestinal Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| indium In 111-labeled autologous peripheral blood mononuclear cells | Radiation | — | UNRESOLVED |
| indium In 111-labeled autologous polymorphonuclear leukocytes | Radiation | — | UNRESOLVED |
| radionuclide imaging | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Number of baseline indium In 111-labeled peripheral blood mononuclear cells (PBMCs) trafficking into tumors
- measure
- Number of baseline indium In 111-labeled polymorphonuclear leukocytes (PMNLs) trafficking into tumors
- measure
- Number of PBMC and PMNL trafficking prior to vs after therapy
- measure
- Cellular uptake of PBMCs and PMNLs as measured by reader/visual interpretation, semiquantitative grading system, and tumor-to-background uptake ratios
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed non-Hodgkin's lymphoma * Indolent or aggressive disease * Planning to receive a new regimen or starting a regimen of cancer therapy * At least one tumor lesion measurable in two dimensions as ≥ 1.5 cm by CT scan PATIENT CHARACTERISTICS: * ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100% * Life expectancy ≥ 3 months * No concurrent medical complications that would preclude study compliance * Not pregnant or nursing PRIOR CONCURRENT THERAPY: * At least 3 weeks since prior chemotherapy (except for nonmyelosuppressive treatments) * At least 3 weeks since prior radiation therapy * Concurrent rituximab allowed
References
Publications (0)
Data not yet available
No reference posted for this study.